(MedPage Today) — A real-world comparison of two androgen receptor pathway inhibitors (ARPIs) for advanced prostate cancer showed a significant difference in overall survival (OS).
Patients with metastatic castration-sensitive prostate cancer…
Source link : https://www.medpagetoday.com/meetingcoverage/additionalmeetings/119784
Author :
Publish date : 2026-02-07 13:00:00
Copyright for syndicated content belongs to the linked Source.














